David Tulasne
  • E-mail :[email]
  • Phone : 03 20 87 12 57
  • Location : Lille, France
Last update 2018-08-22 17:20:04.532

David Tulasne Signalling, Apoptosis and Cancer

Course and current status

Scientific Career and Professional Experiences

Group leader of the team "Signalling, Apoptosis and Cancer" in the UMR8161, CNRS, Institute of Biology of Lille (IBL)

2017                Director of research, INSERM, IBL

2006                Research Associate 1ère classe INSERM, IBL

2002                Research Associate 2ème classe INSERM, IBL

1999 -2001     Postdoctoral researcher, Laboratory of Dr SP. Watson, Department of Pharmacology, University of Oxford, UK.

1995-1999      PhD student. Laboratory of Dr B. Vandenbunder. Régulation des processus invasifs, de l’Angiogenèse et de l’Apoptose. CNRS EP560, IBL.

Academic Education

2005    “Habilitation à diriger des recherches”, University of Lille

1999    PhD, Life Sciences and Heath, University of Lille

1995    Master II, Life Sciences and Heath

1993    Master I Cellular Biology

1992    Licence Biology

Scientific summary

The Hepatocyte growth factor/Scatter Factor (HGF/SF), the specific ligand of the receptor tyrosine kinase Met, induces multiple biological responses including proliferation, invasion, morphogenesis and survival of epithelial cells, which are essential for epithelial homeostasis. Indeed, the HGF/SF-Met system is essential for embryonic development and tissue regeneration in adults. However, deregulated HGF/SF-Met signaling is involved in tumor progression in particular by promoting invasion and metastasis in numerous types of cancer. Our goal is to characterize the molecular mechanism induced by the receptor tyrosine kinase Met to regulate the epithelial homeostasis.

Image d’exemple